According to the Financial Times, MSD – known as Merck & Co in the US and Canada – is in the final stages of a $10 billion ...

Verona has a market capitalisation of about $7.39 billion, according to LSEG data. Merck has long leaned on its blockbuster cancer drug Keytruda, which generated nearly $30 billion in sales in 2024, ...

Merck is nearing a $10 billion deal to buy lung diseases focussed Verona Pharma, as the U.S. drugmaker is eyeing deals to ...

U.S. drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...

Merck would pay $107 per American depository share for Verona, the report said, citing three people familiar with the matter.

US pharma giant seeks to expand footprint beyond cancer treatment as its biggest product nears patent cliff ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Merck’s key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone ...

DelveInsight's, “Melanoma Pipeline Insight” report provides comprehensive insights about 150+ companies and 170+ pipeline ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide ( ) with these numbers expected to grow. The American Cancer Society ...

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...